Introduction {#sec1_1}
============

Lung adenocarcinoma is most often detected in metastatic stage IV, and common sites of metastasis are the brain, liver, bones and adrenal glands \[[@B1]\]. Bone metastases from lung adenocarcinoma occur in about 40% of cases, but only around 3% of bone metastasis are found within the skull bones, including the sphenoid bone \[[@B2], [@B3]\]. This butterfly-shaped bone in the middle of the skull base contains indispensable structures, such as the pituitary gland, optic chiasm, cavernous sinus, internal carotid artery, and cranial nerves II-VI. Metastasis of lung adenocarcinoma to the sphenoid bone is rare and few cases have been reported. We describe an unusual case with trigeminal neuropathy caused by sphenoid bone metastasis from lung adenocarcinoma as the initial symptom.

Case Report {#sec1_2}
===========

A 74-year-old woman, a housewife and non-smoker, presented with a 2-month history of left cheek dysesthesia. She had not complained of any other symptoms such as cough, sputum, general fatigue or visual impairment. Computed tomography (CT) showed a mass around 2.5 cm in diameter with heterogeneous enhancement and bone destruction at the central focus on the left foramen rotundum in the sphenoid bone, extending from the left middle cranial and pterygopalatine fossa to the left orbital apex (Fig. [1a--c](#F1){ref-type="fig"}). Initially, diagnoses of trigeminal schwannoma, meningioma or sinonasal carcinoma were considered. We performed endoscopic sinus surgery under general anesthesia and resected a yellowish mass from the lateral wall of the left sphenoid sinus (Fig. [1d](#F1){ref-type="fig"}). Histopathologic examination revealed proliferation of atypical cells with large irregular nuclei (Fig. [2a](#F2){ref-type="fig"}). Immunohistologic analysis showed tumor cells with positive cytoplasmic staining for AE1/AE3 (Fig. [2b](#F2){ref-type="fig"}), CAM5.2 (Fig. [2c](#F2){ref-type="fig"}), CK7 (Fig. [2d](#F2){ref-type="fig"}) and TTF-1 (Fig. [2e](#F2){ref-type="fig"}). However, negative results were obtained for CK 20 (data not shown). The percentage of Ki-67-positive cells was approximately 30% (Fig. [2f](#F2){ref-type="fig"}). Unexpectedly, these findings indicated a histology consistent with lung adenocarcinoma. We therefore conducted a general search for lesions, including the lungs. Chest CT revealed 4-cm mass with irregular margins in the right upper lung (Fig. [3a](#F3){ref-type="fig"}). Fluorodeoxyglucose (FDG)‑positron emission tomography (PET)/CT revealed a mass with strong uptake in the right lung and ipsilateral upper mediastinum indicating lymph node metastases (Fig. [3b](#F3){ref-type="fig"}). Multiple bone metastases were identified in the left 3rd rib and 1st and 5th lumbar vertebras. In laboratory examinations, serum calcium was 9.1 mg/dl (normal: 8.6--10.2 mg/dL), alkaline phosphatase (ALP) was 769 U/L (normal: 104--338 U/L), carcinoembryonic antigen (CEA) was 32.2 ng/mL (normal: \<5 ng/mL). Genetic analysis revealed only a missense mutation in the epidermal growth factor receptor *(EGFR)* gene (p.L858R) in exon 21. No deletions in exon 19 or 20 of the *EGFR* gene were not identified. KRAS and NRAS mutations were also not identified. The final clinical staging was cT2N1M1c and stage IVB, *EGFR*-mutant lung adenocarcinoma. Oral administration of gefinitib at 250 mg every day proved quite effective. Although cheek dysesthesia remained unrelieved, the patient remains alive without any evident growth of the tumors in the lung or sphenoid bone as of 18 months.

Discussion {#sec1_3}
==========

Metastasis to the sphenoid bone has been reported from lung, breast, prostate, pancreas and thyroid carcinomas \[[@B4]\]. The mechanism underlying metastasis from lung adenocarcinoma to the sphenoid bone is mainly considered to involve hematogenous spread of tumor cells to the bone. In the present case, we suspected that circulating tumor cells might have become trapped in either the cavernous sinus, or vessels accompanying the trigeminal nerve or meninges around the foramen rotundum. The metastatic tumor might have compressed the second branch of the trigeminal nerve, resulting in trigeminal neuropathy and subsequent cheek dysesthesia.

Characteristics of 12 patients with metastasis of lung carcinoma to the sphenoid bone identified from the literature published since 1990 are summarized in the Table [1](#T1){ref-type="table"} \[[@B4], [@B5], [@B6], [@B7], [@B8], [@B9], [@B10], [@B11]\]. Median age of the patients was 63 years (range, 47--76 years). The majority of patients were female (9 females, 3 males). A history of smoking was reported in 4 patients. Adenocarcinoma was the most common histological type, seen in 6 cases (50%).

Metastasis to the sphenoid bone may cause a variety of symptoms, including visual symptoms such as diplopia, ptosis, changes in visual acuity, retro-orbital or frontal headache, and facial dysesthesia. These symptoms naturally varied depending on location, size, and cranial nerves affected by the tumor. The most frequent clinical symptom was headache or pain, appearing in 7 cases (58%), followed by ophthalmological symptoms in 6 cases (50%) and facial symptoms including dysesthesia or pain associated with trigeminal nerve in 5 cases (41%) (Table [1](#T1){ref-type="table"}). Eight (75%) of the 12 patients showed symptoms relating to sphenoid bone metastasis as an initial presentation of the lung carcinoma. Only one report described trigeminal neuropathy caused by metastasis to Meckel\'s cave, site of the ganglion of the trigeminal nerve, resulting in the symptoms seen as the first presentation of lung adenocarcinoma \[[@B8]\]. The reason our patient did not complain of any respiratory symptoms, back pain, or general symptom remains unclear. Primary lung carcinoma would usually be expected to have been discovered at a medical examination before the patient became aware of any symptoms such cheek dysesthesia.

In the present case, we were able to obtain biopsy specimens through the sphenoid sinus and suspected metastasis of lung adenocarcinoma. Immunohistologic analysis plays an important role in confirmating the origin of a carcinoma. A previous study demonstrated that 73% of primary lung adenocarcinomas expressed TTF-1, whereas all non-pulmonary adenocarcinomas lacked TTF-1 staining \[[@B12]\]. CK7 expression is significantly more frequent in adenocarcinomas of lung and breast origin than in those of gastrointestinal origin. In contrast, CK20 expression is significantly more prevalent in adenocarcinomas of gastrointestinal origin than in those of lung or breast origin. The combination of TTF-1+CK7+CK20-- is thus strongly associated with lung adenocarcinoma.

Several treatments have been described in the literature, including radiotherapy and/or chemotherapy with CDDP and gemcitabine. Many recent reports have suggested the effectiveness of EGFR-tyrosine kinase inhibitors (TKIs) in treating lung carcinoma \[[@B13]\]. Gefitinib, a molecularly targeted EGFR-TKI, is reported to have a considerable efficacy in female patients and nonsmokers, especially those with adenocarcinoma \[[@B2]\]. Gefitinib has shown rapid and improved response rate in patients with lung adenocarcinoma with bone metastasis showing EGFR-activating mutations \[[@B2]\].

The prognosis of cases with metastasis to the sphenoid bone from lung carcinoma is quite poor. Seven (58%) of the 12 patients reported were dead within 5 months (Table [1](#T1){ref-type="table"}). Life expectancy after skull metastasis is estimated to be around 5 months \[[@B14]\]. However, treatment with an EGFR-TKI may improve survival after bone metastasis \[[@B2]\]. In the present case with EGFR mutation, administration of EGFR-TKI proved quite effective and our patient remain alive with stable disease. However, in the near future, if pain develops in the face, chest or back, radiotherapy or another drug will be needed.

In conclusion, both physicians and neurologists must be aware of the possibility of trigeminal neuropathy resulting from metastases. Most notably, metastases may be the initial presenting sign of a primary tumor, as in the patient reported here. Adenocarcinoma is the most common histologic subtype of lung carcinoma with metastasis to the skull bone. When encountering tumors in the head and neck region, histological examination and thorough clinical and laboratory investigations should be performed for other primary malignancies, particularly the lung.
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![Computed tomography (CT) shows a mass of around 2.5 cm in maximal diameter with heterogeneous enhancement and bone destruction at the central focus on the left foramen rotundum, extending from the left middle cranial and pterygopalatine fossa to the left orbital apex (**a--c**). A yellowish tumor is observed on the lateral side of the left sphenoid sinus (**d**).](cro-0012-0650-g01){#F1}

![Histopathologic examination with hematoxylin and eosin staining reveals a proliferation of atypical cells with large irregular nuclei (**a**). Immunohistologic analysis shows tumor cells with membrane staining for AE1/AE3 (**b**), CAM5.2 (**c**), CK7 (**d**) and TTF-1 (**e**). The percentage of Ki-67-positive cells is approximately 30% (**f**). Magnification ×400.](cro-0012-0650-g02){#F2}

![CT reveals a 4-cm mass with irregular margins in the right upper lung (**a**). FDG-PET/CT shows strong uptake in not only the primary lung tumor (arrowhead), but also metastatic lymph nodes in the right upper mediastinum (white arrow), left third rib, and 1st and 5th lumbar vertebras (triangles) (**b**).](cro-0012-0650-g03){#F3}

###### 

Reported cases with metastasis to shenoid bone from lung carcinoma

  Author                        Age/Gender   Smoking history   Histology           Symptoms relating to sphenoid sinus                                                 Cranial nerve involvement   Treatment                        Prognosis
  ----------------------------- ------------ ----------------- ------------------- ----------------------------------------------------------------------------------- --------------------------- -------------------------------- ---------------
  Mickel \[[@B4]\], 1990        51/F         NR                Bronchogenic ca.    Ophthalmoplegia, ptosis                                                             II, III, IV, VI             RT, CT                           Dead (1 wk)
                                71/F         NR                Poorly diff. ca.    Headache, diplopia, decreased visual acuity[\*](#T1F1){ref-type="table-fn"}         II, V, VI                   NR                               Dead (5 mo)
                                47/M         NR                Adenocarcinoma      Headache, facial pain[\*](#T1F1){ref-type="table-fn"}                               III, IV, VI                 CDDP, mitomycin-C, vinblastine   Dead (1 mo)
  Weilbaecher \[[@B5]\], 2004   52/F         \+                Small cell ca.      Hemiplasia, ptosis, medial deviation[\*](#T1F1){ref-type="table-fn"}                III                         Gamma knife                      Alive (1 mo)
                                67/F         \+                Small cell ca.      Headache, diplopia[\*](#T1F1){ref-type="table-fn"}                                  VI                          CT                               Dead
  Huang \[[@B6]\], 2009         59/F         \-                Adenocarcinoma      Nasion swelling, nasal stuffness, facial numbness[\*](#T1F1){ref-type="table-fn"}   V2                          CDDP, Gemcitabine                Alive
  Gupta \[[@B7]\], 2011         60/M         NR                Adenocarcinoma      Pain and swelling of eye, diplopia[\*](#T1F1){ref-type="table-fn"}                                              NR                               NR
  Cerase\[[@B8]\],2011          69/M         \+                Adenocarcinoma      Cheek paresthesia[\*](#T1F1){ref-type="table-fn"}                                   V2                          RT                               Dead (2 wks)
  Zelenak \[[@B9]\], 2012       59/F         NR                Squamous cell ca.   Headache, hearing loss, facial pain                                                 III--VIII                   RT, CDDP, taxol                  Dead
  Priddy \[[@B10]\], 2017       66/F         \+                Adenocarcinoma      Headache, fever, CSF rhinorrhea                                                                                 Erlotinib                        Alive (2 mo)
  Fukai \[[@B11]\], 2018        76/F         \-                NSCLC               Headache, diplopia                                                                  IV, V1, VI                  RT                               Dead (5 mo)
  Present case                  74/F         \-                Adenocarcinoma      Cheek dysesthesia[\*](#T1F1){ref-type="table-fn"}                                   V2                          Gefinitib                        Alive (18 mo)

NR, not reported; CT, chemotherapy; RT, radiotherapy; CDDP, cisplatin; NSCLC, non small cell lung carcinoma; CSF, cerebrospinal fluid.

Initial symptom for lung carcinoma prior to respiratory symptoms.
